Autoimmune Diseases  >>  Victoza (liraglutide)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Victoza (liraglutide) / Novo Nordisk
T1DMLIRA, NCT02092896 / 2012-002526-67: Liraglutide as add-on to Insulin in Type 1 Diabetes

Completed
3
40
Europe
Liraglutide, Placebo
Hvidovre University Hospital, NNF Center for Basal Metabolic Research, Denmark, Hillerod Hospital, Denmark, Danish PhD schools of Molecular Metabolism and Endocrinology, Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
10/14
10/14
ADJUNCT TWO, NCT02098395 / 2012-005778-74: The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes

Completed
3
835
US, Canada, Europe, RoW
liraglutide, placebo
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
04/15
04/15
ADJUNCT ONE, NCT01836523 / 2012-003580-21: The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

Completed
3
1398
US, Canada, Europe, RoW
liraglutide, placebo
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
06/15
06/15
NCT01722227: Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes

Withdrawn
3
0
US
Liraglutide, Placebo
University at Buffalo, American Diabetes Association
Type 1 Diabetes
11/17
05/18
NCT00993720: Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes

Completed
2/3
30
Europe
Liraglutide, continuous insulin therapy
Hvidovre University Hospital
Diabetes Mellitus
10/10
10/10

Download Options